1. Market Research
  2. > Pharmaceutical
  3. > OTC Market Trends
  4. > Constipation - Pipeline Review, H1 2017

Constipation - Pipeline Review, H1 2017

  • February 2017
  • -
  • Global Markets Direct
  • -
  • 108 pages

Constipation - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Constipation – Pipeline Review, H1 2017, provides an overview of the Constipation (Gastrointestinal) pipeline landscape.

Constipation refers to the infrequent or difficult passing of stool. Constipation occurs when bowel movements become difficult or less frequent. Symptoms of constipation include swollen abdomen or abdominal pain, pain and vomiting. The predisposing factors include eating disorders, irritable bowel syndrome, and hypothyroidism, overuse of laxatives (stool softeners) which, over time, weaken the bowel muscles, stress, inadequate water intake and inadequate fiber in the diet. Treatment includes use of laxatives and proper lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Constipation – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Constipation (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Constipation (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Constipation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 7, 8, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Constipation (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Constipation (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Constipation (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Constipation (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Constipation (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Constipation (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Constipation (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Constipation (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Constipation - Pipeline Review, H1 2017
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Constipation - Overview
Constipation - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Constipation - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Constipation - Companies Involved in Therapeutics Development
Albireo Pharma Inc
Ardelyx Inc
Assembly Biosciences Inc
Astellas Pharma Inc
Braintree Laboratories Inc
CJ HealthCare Corp
Dong-A Socio Holdings Co Ltd
EA Pharma Co Ltd
Ironwood Pharmaceuticals Inc
Lipid Pharmaceuticals ehf
Motus Therapeutics Inc
NGM Biopharmaceuticals Inc
RaQualia Pharma Inc
Sanwa Kagaku Kenkyusho Co Ltd
Shire Plc
SK Biopharmaceuticals Co Ltd
Sucampo Pharmaceuticals Inc
Sumitomo Dainippon Pharma Co Ltd
Synthetic Biologics Inc
Torrent Pharmaceuticals Ltd
Yuhan Corp
Constipation - Drug Profiles
5-BIOP - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
AJG-555 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
ASP-7663 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Biologic for Irritable Bowel Syndrome with Constipation - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
BLI-400 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
BLI-801 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
CJ-14199 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
DA-6886 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
DSP-6952 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
elobixibat - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
ENT-01 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
J-027 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
linaclotide - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
lovastatin - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
LP-101 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
lubiprostone - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
naronapride - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
NGM-282 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
prucalopride succinate - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
prucalopride succinate - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
relamorelin - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
relenopride hydrochloride - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
RQ-00000010 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
SK-1202 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
tenapanor hydrochloride - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
YH-12852 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Constipation - Dormant Projects
Constipation - Product Development Milestones
Featured News and Press Releases
Feb 01, 2017: Albireo Announces Submission of New Drug Application for Elobixibat in Japan
Jan 30, 2017: Astellas and Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial for Patients with Chronic Constipation Conducted in Japan
Jan 26, 2017: U.S. Food and Drug Administration Approves 72 mcg Dose of LINZESS (linaclotide) for Adults with Chronic Idiopathic Constipation
Dec 22, 2016: Ironwood and Allergan Report Topline Phase IIb Data Supporting Advancement of Linaclotide Colonic Release-1 (CR1) in IBS-C
Nov 16, 2016: Renexxion Achieves Positive FDA Guidance for Phase 3-ready GI Drug Naronapride
Oct 19, 2016: Ardelyx Announces the Presentation of Positive Global Endpoint Findings from Phase 2b Trial of Tenapanor in Patients with IBS-C at ACG Annual Meeting
Oct 03, 2016: Albireo Announces Positive Top-Line Phase 3 Results for Elobixibat in Japan
Sep 30, 2016: EA Pharma and Mochida Pharmaceutical Announce the Results of Phase 3 Study of AJG533 for Chronic Constipation Conducted in Japan
Aug 19, 2016: The First Dosing of RQ-00000010 at Virginia Commonwealth University Initiated
Aug 02, 2016: Synthetic Biologics Announces Completion of End of Phase 2 Meeting with FDA for SYN-010, Intended for the Treatment of Irritable Bowel Syndrome with Constipation
Jun 09, 2016: Ironwood and Allergan Announce Supplemental New Drug Application for 72 mcg Linaclotide in Chronic Idiopathic Constipation Has Been Accepted for FDA Review
May 23, 2016: Synthetic Biologics Announces Detailed Data from Two SYN-010 Phase 2 Clinical Trials for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
May 17, 2016: Ironwood Pharmaceuticals to Present Linaclotide Data at Digestive Disease Week 2016
May 17, 2016: Synthetic Biologics to Host Post-DDW 2016 Conference Call to Recap SYN-010 Phase 2 Clinical Trial Results for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
May 11, 2016: Isaac J. Bright, MD, Joins Synthetic Biologics as Vice President, Corporate Development
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Constipation, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Constipation - Pipeline by Albireo Pharma Inc, H1 2017
Constipation - Pipeline by Ardelyx Inc, H1 2017
Constipation - Pipeline by Assembly Biosciences Inc, H1 2017
Constipation - Pipeline by Astellas Pharma Inc, H1 2017
Constipation - Pipeline by Braintree Laboratories Inc, H1 2017
Constipation - Pipeline by CJ HealthCare Corp, H1 2017
Constipation - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
Constipation - Pipeline by EA Pharma Co Ltd, H1 2017
Constipation - Pipeline by Ironwood Pharmaceuticals Inc, H1 2017
Constipation - Pipeline by Lipid Pharmaceuticals ehf, H1 2017
Constipation - Pipeline by Motus Therapeutics Inc, H1 2017
Constipation - Pipeline by NGM Biopharmaceuticals Inc, H1 2017
Constipation - Pipeline by RaQualia Pharma Inc, H1 2017
Constipation - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H1 2017
Constipation - Pipeline by Shire Plc, H1 2017
Constipation - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017
Constipation - Pipeline by Sucampo Pharmaceuticals Inc, H1 2017
Constipation - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
Constipation - Pipeline by Synthetic Biologics Inc, H1 2017
Constipation - Pipeline by Torrent Pharmaceuticals Ltd, H1 2017
Constipation - Pipeline by Yuhan Corp, H1 2017
Constipation - Dormant Projects, H1 2017

List of Figures
Number of Products under Development for Constipation, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2017

Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2017

  • $ 2000
  • Company report
  • March 2017
  • by Global Markets Direct

Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opioid-Induced Constipation (OIC) – Pipeline Review, ...

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2017

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2017

  • $ 2000
  • Company report
  • February 2017
  • by Global Markets Direct

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Reflux Esophagitis (Gastroesophageal ...

Diarrhea - Pipeline Review, H1 2017

Diarrhea - Pipeline Review, H1 2017

  • $ 2000
  • Company report
  • February 2017
  • by Global Markets Direct

Diarrhea - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diarrhea – Pipeline Review, H1 2017, provides an overview of the Diarrhea ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.